APRE — Aprea Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1781983 ·
Last close
$0.62
Market Cap
$7.68M
52W High
$1.06
52W Low
$0.60
ADV30
73,000
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -3,430,412 | -3,287,917 | 47,612,387 | 46,466,202 | 6,024,007 |
| Dec 2025 | 0 | — | -2,643,093 | -2,455,630 | 15,933,401 | 14,599,347 | 3,491,719 |
| Sep 2025 | 0 | — | -3,117,388 | -2,972,410 | 14,321,316 | 13,718,052 | 3,408,468 |
| Jun 2025 | 0 | — | -3,387,773 | -3,238,870 | 17,309,710 | 16,532,199 | 3,895,029 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-12,020,002
Investing CF
$0
Financing CF
$39,208,538
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.54
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-336,929,358
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-12,578,666
Pretax Income TTM
$-11,954,827
Interest Exp TTM
—
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$123,296
EBITDA
$-12,556,952
Free Cash Flow
$-5,625,328
Enterprise Value
$-38,061,520
Total Cash
$46,466,200
Total Debt
$0
Shares Out
12,382,776
Trailing EPS
$-1.49
Book Value
$3.47
ROE
-40.4%
ROA
-23.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -13,233,836 | -12,599,569 | 15,933,401 | 3,491,719 | — | -12,894,439 |
| Dec 2024 | 0 | -14,319,655 | -12,958,711 | 23,979,493 | 4,672,038 | — | -13,556,718 |
| Dec 2023 | 0 | -15,471,963 | -14,286,756 | 22,650,174 | 5,696,668 | — | -12,177,608 |
| Dec 2022 | 0 | -37,372,044 | -112,662,027 | 30,155,827 | 4,512,149 | — | -25,011,136 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.79
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BOLT | Bolt Biotherapeutics, Inc. | $7.67M | $3.99 | — |
| APUS | Apimeds Pharmaceuticals US, Inc. | $7.77M | $5.15 | — |
| INM | InMed Pharmaceuticals Inc. | $7.85M | $1.47 | — |
| MTVA | MetaVia Inc. | $7.33M | $1.42 | — |
| ADIL | ADIAL PHARMACEUTICALS, INC. | $7.31M | $3.34 | — |
News headlines (Yahoo Finance, 1h cache)
Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026
2026-07-30 12:00 · Yahoo
Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors
2026-06-01 12:00 · Yahoo
Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
2026-05-13 10:30 · Yahoo
Oracle upgraded, Planet Fitness downgraded: Wall Street's top analyst calls
2026-05-07 13:45 · Yahoo
Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting
2026-04-21 14:15 · Yahoo
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement
2026-04-01 12:30 · Yahoo
Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement
2026-03-30 12:01 · Yahoo
Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial
2026-03-30 12:00 · Yahoo
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
2026-03-16 12:00 · Yahoo
Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial
2026-02-18 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.